EGFR and triple-negative breast carcinoma: This includes the anti-EGFR cetuximab in metastatic colon cancer, head and neck cancer (HNSCC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), the anti-CD20 rituximab in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), and the anti-PD-L1 avelumab in pancreatic cancer, HNSCC, and NSCLC [9, 107–110].